Tardive Dyskinesia
Tardive dyskinesia (TD) is an abnormal involuntary movement disorder that arises as a common adverse effect in patients using antipsychotic medications, occurring in an estimated 20% of this population. This condition inflicts a substantial negative impact on patient quality of life and clinical outcomes and contributes to the significant rate of nonadherence to antipsychotic medication regimens.
Tardive Dyskinesia 360 is a resource center built for mental health practitioners, designed to educate providers on the proper screening, diagnosis, and treatment of TD. Explore expert video commentary, patient cases activities, instructional videos, and stay up to date on the latest information related to TD care.
This initiative is supported by independent educational grants from Neurocrine Biosciences and Teva Pharmaceuticals.
Videos
Abnormal Involuntary Movement Scale (AIMS) Exam
Psych Congress co-chair Rakesh Jain, MD, MPH, explains the importance of the Abnormal Involuntary Movement Scale (AIMS) exam in the diagnosis and monitoring of patients with tardive dyskinesia.
Abnormal Involuntary Movement Scale (AIMS) Exam
From normal (0) to severe (4), see what real tardive dyskinesia movements look like so you can better assess your patients.
Treatment Discussion Points
Drs. Jain and Kumar provide and in-depth analysis of two new VMAT2 inhibitors approved to treat tardive dyskinesia.
Articles
A selective vesicular monoamine transporter 2 (VMAT2) inhibitor can improve symptoms of moderate to severe tardive dyskinesia (TD), posters presented at Psych Congress suggest.
In this new, occasional feature, members of the Psych Congress Steering Committee answer questions asked by audience members at Psych Congress meetings. In this installment, cochair Rakesh…
The US Food and Drug Administration has approved deutetrabenazine for the treatment of tardive dyskinesia in adults, Teva Pharmaceutical Industries announced.
NEW ORLEANS—Researchers have developed a new scale to measure the impacts tardive dyskinesia has on patients and their caregivers, according to a poster abstract presented at Psych Congress 2017.
An analysis of blood serum has identified differences between patients with tardive dyskinesia (TD) and people who have not developed the movement disorder.
Posters
This trial will evaluate the efficacy, safety and tolerability of fixed-dose regimens of deutetrabenazine for the treatment of TD, which may facilitate dose titration and decrease treatment burden.
In patients with moderate/severe TD, deutetrabenazine was associated with a reduction in abnormal, involuntary movements in 6 of the 7 areas evaluated.
In ARM-TD, a higher proportion of deutetrabenazine patients were responders compared with placebo, defined by percent improvement on AIMS from baseline to Week 12.
KINECT 3 (NCT02274558), a 6-week, double-blind, placebo-controlled study, was conducted in subjects with moderate-to-severe TD and underlying schizophrenia, schizoaffective disorder, or mood disorder.
Concept elicitation interviewing techniques were utilized with patients and caregivers to elicit the TD experience, and cognitive interviewing techniques were utilized to test a patient-reported…